Zhang Wei, Wang Xiaobing, Liu Yi, Tian Haimei, Flickinger Brent, Empie Mark W, Sun Sam Z
Tumor Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
J Med Food. 2008 Jun;11(2):207-14. doi: 10.1089/jmf.2007.602.
A flaxseed lignan extract containing 33% secoisolariciresinol diglucoside (SDG) was evaluated for its ability to alleviate lower urinary tract symptoms (LUTS) in 87 subjects with benign prostatic hyperplasia (BPH). A randomized, double-blind, placebo-controlled clinical trial with repeated measurements was conducted over a 4-month period using treatment dosages of 0 (placebo), 300, or 600 mg/day SDG. After 4 months of treatment, 78 of the 87 subjects completed the study. For the 0, 300, and 600 mg/day SDG groups, respectively, the International Prostate Symptom Score (IPSS) decreased -3.67 +/- 1.56, -7.33 +/- 1.18, and -6.88 +/- 1.43 (mean +/- SE, P = .100, < .001, and < .001 compared to baseline), the Quality of Life score (QOL score) improved by -0.71 +/- 0.23, -1.48 +/- 0.24, and -1.75 +/- 0.25 (mean +/- SE, P = .163 and .012 compared to placebo and P = .103, < .001, and < .001 compared to baseline), and the number of subjects whose LUTS grade changed from "moderate/severe" to "mild" increased by three, six, and 10 (P = .188, .032, and .012 compared to baseline). Maximum urinary flows insignificantly increased 0.43 +/- 1.57, 1.86 +/- 1.08, and 2.7 +/- 1.93 mL/second (mean +/- SE, no statistical significance reached), and postvoiding urine volume decreased insignificantly by -29.4 +/- 20.46, -19.2 +/- 16.91, and -55.62 +/- 36.45 mL (mean +/- SE, no statistical significance reached). Plasma concentrations of secoisolariciresinol (SECO), enterodiol (ED), and enterolactone (EL) were significantly raised after the supplementation. The observed decreases in IPSS and QOL score were correlated with the concentrations of plasma total lignans, SECO, ED, and EL. In conclusion, dietary flaxseed lignan extract appreciably improves LUTS in BPH subjects, and the therapeutic efficacy appeared comparable to that of commonly used intervention agents of alpha1A-adrenoceptor blockers and 5alpha-reductase inhibitors.
对一种含有33%开环异落叶松脂素二葡萄糖苷（SDG）的亚麻籽木脂素提取物进行了评估，以观察其缓解87例良性前列腺增生（BPH）患者下尿路症状（LUTS）的能力。在4个月的时间里，进行了一项随机、双盲、安慰剂对照且重复测量的临床试验，使用的治疗剂量为0（安慰剂）、300或600毫克/天的SDG。治疗4个月后，87名受试者中有78名完成了研究。对于每日服用0、300和600毫克SDG的组，国际前列腺症状评分（IPSS）分别下降了-3.67±1.56、-7.33±1.18和-6.88±1.43（平均值±标准误，与基线相比，P = 0.100、<0.001和<0.001），生活质量评分（QOL评分）改善了-0.71±0.23、-1.48±0.24和-1.75±0.25（平均值±标准误，与安慰剂相比，P = 0.163和0.012，与基线相比，P = 0.103、<0.001和<0.001），LUTS分级从“中度/重度”变为“轻度”的受试者数量分别增加了3、6和10例（与基线相比，P = 0.188、0.032和0.012）。最大尿流率分别显著增加了0.43±1.57、1.86±1.08和2.7±1.93毫升/秒（平均值±标准误，未达到统计学显著性），排尿后残余尿量分别显著减少了-29.4±20.46、-19.2±16.91和-55.62±36.45毫升（平均值±标准误，未达到统计学显著性）。补充后，血浆中开环异落叶松脂素（SECO）、肠二醇（ED）和肠内酯（EL）的浓度显著升高。观察到的IPSS和QOL评分的下降与血浆总木脂素、SECO、ED和EL的浓度相关。总之，膳食亚麻籽木脂素提取物可显著改善BPH患者的LUTS，其治疗效果似乎与常用的α1A肾上腺素能受体阻滞剂和5α还原酶抑制剂相当。
